VivoSeq
Other

Advanced NSCLC

0

Pipeline Programs↗

58

Active Trials↗

32

Companies Involved↗

Advanced NSCLC is an early-stage landscape with 0 programs across 32 companies. The most active players are Mirati Therapeutics Inc., AstraZeneca, Betta Pharmaceuticals Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

30/100

Mech. Concentration

N/A

Completion Rate

71/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Mirati Therapeutics Inc.

1 program

Phase 2AstraZeneca logo

AstraZeneca

0 programs

PreclinicalB

Betta Pharmaceuticals Co., Ltd.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalD

Dizal Pharmaceuticals

0 programs

PreclinicalAmgen logo

Amgen

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

162

clinical trials

Unknown status48 · 30%
Completed40 · 25%
Recruiting30 · 19%
Not yet recruiting15 · 9%
Terminated13 · 8%
Active, not recruiting12 · 7%
Other4 · 2%

Clinical Trials

Trial Activity

162 trials

Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT05060796·11 enrolled
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
Recruiting·HHunan Province Tumor Hospital·Phase 2·NCT04322578·120 enrolled
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
Recruiting·DDizal Pharmaceuticals·Phase 1·NCT06905197·140 enrolled
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
Recruiting·HHunan Province Tumor Hospital·Phase 2·NCT06348927·52 enrolled
A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients
Recruiting·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 2·NCT06361927·120 enrolled
Lifei Xiaoji Wan in Treatment of Advanced NSCLC
Recruiting·HHenan University of Traditional Chinese Medicine·N/A·NCT06406166·100 enrolled
Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations
Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06062823·35 enrolled
Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
Recruiting·DDizal Pharmaceuticals·Phase 1·NCT06813365·190 enrolled
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Recruiting·Amgen logoAmgen·Phase 2·NCT06593522·200 enrolled
Study of High Efficient Killing Cell Therapy for Advanced NSCLC
Recruiting·RRuijin Hospital·Phase 1·NCT03193567·15 enrolled
THIO Sequenced With Cemiplimab in Advanced NSCLC
Recruiting·MMaia Biotechnology·Phase 2·NCT05208944·227 enrolled
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study
Recruiting·—·Phase 4·NCT04401059·744 enrolled
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
Recruiting·HHunan Province Tumor Hospital·Phase 2·NCT06355609·100 enrolled
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Recruiting·CCellSight Technologies, Inc.·Phase 2·NCT06107374·20 enrolled
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Recruiting·SSecond Xiangya Hospital of Central South University·Phase 2·NCT06951646·70 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)